Advertisement

Topics

Biosimilar User Fee Act reauthorization

05:42 EDT 23 Sep 2016 | Generics and Biosimilars Initiative

On 16 September 2016, the US Food and Drug Administration (FDA) released the Biosimilar User Fee Act II (BsUFA II) performance goals letter, attracting support from industry associations.

Original Article: Biosimilar User Fee Act reauthorization

NEXT ARTICLE

More From BioPortfolio on "Biosimilar User Fee Act reauthorization"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...